Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nab-paclitaxel + carboplatin + pembrolizumab for unresectable or metastatic female reproductive tract melanoma
ChiCTR2000036001Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Sep 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, carboplatin and pembrolizumab in melanoma, sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: objective response rate. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on ChiCTR2000036001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036001.